ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

NASDAQ:RPRX • GB00BMVP7Y09

45.12 USD
+0.01 (+0.02%)
At close: Feb 20, 2026
45.12 USD
0 (0%)
After Hours: 2/20/2026, 8:03:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to RPRX. RPRX was compared to 193 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are some minor concerns on its financial health. RPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • RPRX had positive earnings in the past year.
  • RPRX had a positive operating cash flow in the past year.
  • In the past 5 years RPRX has always been profitable.
  • In the past 5 years RPRX always reported a positive cash flow from operatings.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

1.2 Ratios

  • With an excellent Return On Assets value of 3.93%, RPRX belongs to the best of the industry, outperforming 85.42% of the companies in the same industry.
  • RPRX has a better Return On Equity (11.90%) than 86.46% of its industry peers.
  • RPRX has a better Return On Invested Capital (6.49%) than 84.90% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.64%.
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROIC 6.49%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • RPRX has a Profit Margin of 32.42%. This is amongst the best in the industry. RPRX outperforms 95.31% of its industry peers.
  • RPRX's Profit Margin has improved in the last couple of years.
  • RPRX has a better Operating Margin (65.58%) than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of RPRX has declined.
Industry RankSector Rank
OM 65.58%
PM (TTM) 32.42%
GM N/A
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for RPRX has been reduced compared to 1 year ago.
  • Compared to 5 years ago, RPRX has more shares outstanding
  • RPRX has a worse debt/assets ratio than last year.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.80, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.80, RPRX is in the better half of the industry, outperforming 61.98% of the companies in the same industry.
  • RPRX has a debt to FCF ratio of 11.30. This is a negative value and a sign of low solvency as RPRX would need 11.30 years to pay back of all of its debts.
  • RPRX has a better Debt to FCF ratio (11.30) than 79.69% of its industry peers.
  • RPRX has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of RPRX (1.32) is worse than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Altman-Z 1.8
ROIC/WACC0.75
WACC8.65%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B

2.3 Liquidity

  • RPRX has a Current Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RPRX (2.40) is comparable to the rest of the industry.
  • RPRX has a Quick Ratio of 2.40. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.40, RPRX is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.4
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 8.05% over the past year.
  • The Earnings Per Share has been growing slightly by 0.60% on average over the past years.
  • The Revenue has been growing slightly by 5.06% in the past year.
  • Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 2.30% on average per year.
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%

3.2 Future

  • Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.82% on average per year.
  • RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.88% yearly.
EPS Next Y17.09%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
EPS Next 5Y10.82%
Revenue Next Year4.65%
Revenue Next 2Y4.83%
Revenue Next 3Y5.2%
Revenue Next 5Y8.88%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.19, the valuation of RPRX can be described as reasonable.
  • Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.15% of the companies in the same industry.
  • RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • With a Price/Forward Earnings ratio of 8.70, the valuation of RPRX can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RPRX indicates a rather cheap valuation: RPRX is cheaper than 90.63% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, RPRX is valued rather cheaply.
Industry RankSector Rank
PE 10.19
Fwd PE 8.7
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 82.29% of the companies in the same industry are more expensive than RPRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 32.88
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • RPRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as RPRX's earnings are expected to grow with 16.12% in the coming years.
PEG (NY)0.6
PEG (5Y)17.01
EPS Next 2Y15.54%
EPS Next 3Y16.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • RPRX has a Yearly Dividend Yield of 2.08%.
  • Compared to an average industry Dividend Yield of 1.07, RPRX pays a better dividend. On top of this RPRX pays more dividend than 92.71% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, RPRX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.08%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 49.06% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.06%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/20/2026, 8:03:34 PM)

After market: 45.12 0 (0%)

45.12

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners81.5%
Inst Owner Change7.14%
Ins Owners1.56%
Ins Owner Change8.14%
Market Cap26.05B
Revenue(TTM)2.38B
Net Income(TTM)770.95M
Analysts85.71
Price Target48.57 (7.65%)
Short Float %6.82%
Short Ratio6.48
Dividend
Industry RankSector Rank
Dividend Yield 2.08%
Yearly Dividend0.65
Dividend Growth(5Y)N/A
DP49.06%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.34%
Min EPS beat(2)8.69%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-9.55%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.66%
EPS beat(12)9
Avg EPS beat(12)0.82%
EPS beat(16)10
Avg EPS beat(16)-0.51%
Revenue beat(2)1
Avg Revenue beat(2)-7.72%
Min Revenue beat(2)-23.38%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-23.38%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-7.18%
Revenue beat(12)3
Avg Revenue beat(12)-9.25%
Revenue beat(16)3
Avg Revenue beat(16)-10.51%
PT rev (1m)4.81%
PT rev (3m)5.59%
EPS NQ rev (1m)4.64%
EPS NQ rev (3m)3.74%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)94.83%
Revenue NQ rev (3m)92.45%
Revenue NY rev (1m)2.96%
Revenue NY rev (3m)5.18%
Valuation
Industry RankSector Rank
PE 10.19
Fwd PE 8.7
P/S 10.95
P/FCF 32.88
P/OCF 10.46
P/B 4.02
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)4.43
EY9.82%
EPS(NY)5.19
Fwd EY11.5%
FCF(TTM)1.37
FCFY3.04%
OCF(TTM)4.31
OCFY9.56%
SpS4.12
BVpS11.22
TBVpS9.62
PEG (NY)0.6
PEG (5Y)17.01
Graham Number33.44
Profitability
Industry RankSector Rank
ROA 3.93%
ROE 11.9%
ROCE 8.21%
ROIC 6.49%
ROICexc 7.04%
ROICexgc 7.44%
OM 65.58%
PM (TTM) 32.42%
GM N/A
FCFM 33.31%
ROA(3y)5.19%
ROA(5y)3.87%
ROE(3y)13.89%
ROE(5y)10.63%
ROIC(3y)6.59%
ROIC(5y)6.19%
ROICexc(3y)7.21%
ROICexc(5y)6.98%
ROICexgc(3y)7.34%
ROICexgc(5y)7.06%
ROCE(3y)8.34%
ROCE(5y)7.84%
ROICexgc growth 3Y10.47%
ROICexgc growth 5Y-5.87%
ROICexc growth 3Y8.49%
ROICexc growth 5Y-6.85%
OM growth 3Y16.71%
OM growth 5Y-3.47%
PM growth 3Y156.85%
PM growth 5Y6.8%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 11.3
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 71.39%
Interest Coverage -5.64
Cash Conversion N/A
Profit Quality 102.74%
Current Ratio 2.4
Quick Ratio 2.4
Altman-Z 1.8
F-Score5
WACC8.65%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)90.64%
Cap/Sales(5y)89.1%
Profit Quality(3y)70.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.05%
EPS 3Y6.47%
EPS 5Y0.6%
EPS Q2Q%27.83%
EPS Next Y17.09%
EPS Next 2Y15.54%
EPS Next 3Y16.12%
EPS Next 5Y10.82%
Revenue 1Y (TTM)5.06%
Revenue growth 3Y2.06%
Revenue growth 5Y2.3%
Sales Q2Q%4.71%
Revenue Next Year4.65%
Revenue Next 2Y4.83%
Revenue Next 3Y5.2%
Revenue Next 5Y8.88%
EBIT growth 1Y20.66%
EBIT growth 3Y19.11%
EBIT growth 5Y-1.25%
EBIT Next Year12.12%
EBIT Next 3Y11.79%
EBIT Next 5Y11.11%
FCF growth 1Y200.85%
FCF growth 3Y25.33%
FCF growth 5YN/A
OCF growth 1Y-10.08%
OCF growth 3Y5.11%
OCF growth 5Y4.12%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.19 and the Price/Book (PB) ratio is 4.02.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.06%.